mRESVIA (mRNA-1345)

mRESVIA (mRNA-1345) is a messenger RNA-based vaccine developed to protect adults aged 60 years and older against respiratory syncytial virus (RSV), a common and potentially serious respiratory infection. As part of the innovative mRNA vaccine platform, mRESVIA encodes stabilized prefusion F glycoproteins of RSV subtypes A and B, triggering a robust immune response to prevent RSV-related lower respiratory tract disease. Individuals looking to buy mRESVIA can rely on its clinically demonstrated efficacy and safety, positioning the mRESVIA vaccine as a significant advancement in adult respiratory health.

Directions

mRESVIA is administered as a single intramuscular injection, typically into the deltoid muscle. It should be given by a qualified healthcare professional in accordance with national immunization guidelines. Patients are advised to remain under observation for at least 15 minutes after administration to monitor for any immediate adverse reactions. The timing and eligibility for vaccination should be determined by a medical provider based on individual health status and local RSV prevalence.

Ingredients

The active component of mRESVIA is mRNA-1345, which consists of a lipid nanoparticle-encapsulated messenger RNA sequence encoding the stabilized prefusion F glycoproteins from RSV A and RSV B. Inactive ingredients include lipids (SM-102, cholesterol, DSPC, and PEG2000-DMG), buffer components (tromethamine, tromethamine hydrochloride), acetic acid, sodium acetate, and sucrose.

Cautions

Before administering mRESVIA, healthcare providers should evaluate patients for a history of hypersensitivity reactions, immunocompromising conditions, or concurrent illnesses that may affect vaccine response. While the mRESVIA vaccine is well tolerated in clinical trials, ongoing pharmacovigilance is essential. Patients should be informed about the mRESVIA cost and availability in their region, as pricing may vary depending on insurance coverage and distribution channels. Providers should report any adverse events following immunization to the appropriate regulatory authority.

Contraindications

mRESVIA is contraindicated in individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine. It should not be administered to those experiencing moderate or severe acute illness at the time of vaccination, including individuals with febrile conditions, unless directed otherwise by a healthcare provider.

Side Effects

Commonly reported side effects following administration of mRESVIA include:

• Pain or swelling at the injection site
• Fatigue
• Headache
• Muscle pain
• Joint pain
• Chills
• Fever

Most side effects are mild to moderate and resolve within a few days. Severe allergic reactions are rare but require immediate medical attention.